History of Berlirem

• In 2014, Berlirem GmbH was founded. The company followed the aim to improve and optimize the treatment of Parkinson´s Disease (PD) with L-DOPA (LD). The marketed therapies did not meet the aim to reach a constant dopaminergic stimulation (CDS) in patients. The approach of Neuroderm to administer L-DOPA as an alkaline subcutaneous solution (2013) was judged as unsuitable because of narrow local tolerance and patient´s acceptance. Berlirem decided to invest into research of patentable, highly water-soluble LD-esters.

• The primary explorations centered around a Glycerol-LD ester and Penta-Erithrol-LD ester, alongside other polyalcohol LD-esters. A collaboration with Innovent (Jena) was established.

• From 2018 to 2020, Berlirem entered a license agreement with Britannia, aiming to develop highly soluble LD esters for subcutaneous infusion to ensure CDS in PD patients. Meanwhile (and as expected by the Berlirem team), Neuroderm had to modify its developmental system: two sc-infusion sites and the reduction of carbidopa (CD) for tolerance improvement were needed. The LD/CD mass ratio was 8:1. Another player in this area was ABBVIE, who
  published first results with ABBV-951 in 2019. With a mixture of phosphate esters of L-DOPA and carbidopa the company claimed that higher LD levels were achieved by subcutaneous infusion of the phosphate esters due to an apparently better skin tolerability.

• After separation from Britannia, Berlirem developed a system of small clinical-PK studies in volunteers for rapid selection of the development candidate and for other decisions in terms of decarboxylase (AADC) and COMT inhibitors. During this program we selected Penta-LD as development candidate (over Gly-LD), determined the relative potencies of Benserazide and Carbidopa, quantified the LD-bioavailability of add-on of Opicapone (OC) and calculated the half-life increases after thorough inhibition of levodopa degradation.

• On basis of the accumulated know-how, Berlirem proposes an optimized treatment schedule for CDS suited for all grades of PD. It consists of sc-infusion of LD in much lower daily doses than needed with the sc infusion products of AbbVie (ABBV-951) and Tanabe/NeuroDerm (ND0612) thereby preventing skin tolerance problems. The dose lowering effect is presumably achieved by an optimized AADC-inhibition (dose and dose distribution).

• After AbbVie´s Produodopa® became available in Europe we demonstrated in volunteers that combining a subcutaneous infusion of Produodopa® with thorough inhibition of peripheral LD degradation can triple the achievable levodopa plasma levels and extend its half-live to 4-5 hours compared to the Produodopa® infusion alone.

• The new treatment scheme (BRM-203) has been filed for patent application in the EU.

• In 2023, the patent for BRM-203 was granted, entering the PCT phase. Berlirem initiated a search for (strategic) partnerships to further advance its innovative endeavors.